How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

217 results for

Hemorrhoid Coagulation

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

the study and up to 90 days after their last dose of study drug. Exclusion Criteria: History of malignant disease, including solid tumors and hematologic malignancies. Clinically significant current active infection or serious infection. History of gastrointestinal bleeding, peptic ulcer disease, hemorrhoids or epistaxis. Personal or family history of any bleeding disorder, and/or coagulation profile results outside of normal limits. Known allergy or hypersensitivity to warfarin. Contacts and Locations

2012 Clinical Trials

162. Anfibatide Phase 1 Clinical Trial in Healthy Volunteers

Study Description Go to Brief Summary: In this 94 healthy subjects Phase I clinical trial, we assess the clinical profile of Anfibatide, a specific glycoprotein Ib antagonist. This study represents the first clinical evidence that Anfibatide exhibits strong anti-platelet effects, excellent reversibility, and low bleeding potential in healthy human subjects. Condition or disease Intervention/treatment Phase Coronary Heart Disease Coagulation Disorder Drug: Anfibatide Phase 1 Study Design Go to Layout (...) medical history: no history of heart, liver, kidney, digestive tract, nervous system and metabolic disorder, or ulcer, significant hemorrhage, without the history of drug allergy and postural hypotension; 4) Medical examinations: with normal results in overall examinations (including heart rate, blood pressure, auscultation of heart and lung, palpation of liver and spleen, hepatic and renal function, hematology, coagulation function, urine analysis, stool analysis and occult blood test

2012 Clinical Trials

164. Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

to men, and only to women who opt for rectal sampling: Abnormalities of the colorectal mucosa or significant colorectal symptom(s), which in the opinion of the study investigator represent a contraindication to biopsy (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids) Per participant report at screening, anticipated use and/or unwillingness to abstain from the following (...) days prior to rectal biopsies and for 7 days after biopsies Per participant report at screening, anticipated use and/or unwillingness to abstain from the following medications for a period of 10 days before a biopsy procedure: aspirin (daily use of low-dose aspirin [no more than 81 mg] is allowed at the discretion of the Investigator of Record) or non-steroidal anti-inflammatory drugs (NSAIDS) Abnormal laboratory results for coagulation tests that may indicate an increased risk of bleeding

2012 Clinical Trials

165. Phase 1 Single Dose Escalation Study of CTB-001

Drug: CTB-001 IV bolus or IV infusion Outcome Measures Go to Primary Outcome Measures : Safety [ Time Frame: Up to 7 hours ] Summary statistics for SAD parts will be prepared for measured values and changes from baseline values for each dose group. Placebo subjects will serve as the control. Summaries of treatment-emergent and clinically important abnormalities in ECG, physical examination, vital signs, and laboratory (clinical chemistry, hematology, coagulation, urinalysis) data will be provided (...) disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or cognitive disorders. History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or disorders of absorption, distribution, metabolism, excretion. History of known hypersensitivity to drugs including CTB-001 Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff

2012 Clinical Trials

166. Difference in Pain Perception by Patients With Prostate Biopsy Using Instillagel Compared With Guided Ultrasound Gel

Volunteers: No Criteria Inclusion Criteria: outpatient ultrasound guide prostate biopsy > 40 years old. Good knowledge of dutch language Exclusion Criteria: coagulation disorders disorders of the rectum like hemorrhoids, anal fistula, proctitis, rectal polyps and rectal cancer. treated for active urinary tract infection known of allergy to lidocaine taking antidepressants using anaesthetic agents neurological disorders such as Parkinsons disease, hernias and spinal cord injury treated with radiotherapy

2011 Clinical Trials

167. Comparison of Ligasure Hemorrhoidectomy with Conventional Ferguson's Hemorrhoidectomy. (Full text)

hemorrhoidectomy (28 patients) or Ferguson's hemorrhoidectomy (20 patients). The hemorrhoidal predicle was coagulated with Ligasure™ in the Ligasure™ group and transfied with 2/0 chromic catgut in Ferguson's method. In comparison with Ferguson's method, Ligasure™ hemorrhoidectomy had a shorter operating time (29 vs 12.5 min), less blood loss (22 vs 11.5 ml), less post operative pain as measured on VAS scale and less postoperative complications including hemorrhage (10% vs 3.5%), urinary retention (10% vs 3.5 (...) %) and wound breakdown (20% vs 14%). The submucosal dissection technique with Ligasure™ coagulation of the hemorrhoidal pedicle is safe and effective. The blood vessels and tissue are reduced to a wafer thin seal with good hemostasis. Suturing is not required as the mucosal tissue over the pedicle is sealed off with the current. There is minimal lateral spread of either thermal or electrical energy. The external components of the hemorrhoids can also be treated at the same time. Because of its ease of use

2011 The Indian journal of surgery PubMed

168. Efficacy and Tolerability of the Use of Varicell Compared With Daflon

, 2011 Sponsor: Vidfarma Indústria de Medicamentos Ltda. Information provided by: Vidfarma Indústria de Medicamentos Ltda. Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the efficacy and tolerability of Varicell compared to Daflon, in reducing the symptoms caused by chronic venous insufficiency and hemorrhoidal syndrome. Condition or disease Intervention/treatment Phase Chronic Venous Insufficiency Hemorrhoids Drug: Daflon Drug: Varicell placebo Phase 3 (...) Detailed Description: To evaluate the efficacy of Varicell compared with Daflon in the symptomatic treatment of chronic venous insufficiency and hemorrhoidal syndrome. To evaluate the tolerability of the use of Varicell compared with Daflon in the symptomatic treatment of chronic venous insufficiency and hemorrhoidal syndrome. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 102 participants Allocation: Randomized Intervention

2011 Clinical Trials

169. A Double Blinded Study to Examine the Effect of Coated Suppositories on Fecal Incontinence in Patients With Spinal Cord Injury

. History of HIV, hepatitis B, hepatitis. Has used, in the last four weeks, drugs that may affect blood coagulation, such as Aspirin (at a dose above 250 mg/day), Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine. Use of tricyclic or monoamine-oxidase inhibors. Has upon physical examination a rectal deformation or signs of rectal disease such as fissure, bleeding hemorrhoids, fistula, infection or space occupying lesion. Unable to understand the use instruction for the coated

2011 Clinical Trials

170. A Double Blinded Study to Examine the Effect of Alpha Agonist Ointment on Fecal Incontinence in Patients With Idiopathic Fecal Incontinence

, hepatitis. Has used, in the last four weeks, drugs that may affect blood coagulation, such as Aspirin (at a dose above 250 mg/day), Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine. Use of tricyclic or monoamine-oxidase inhibitors. Has upon physical examination a rectal deformation or signs of rectal disease such as fissure, bleeding hemorrhoids, fistula., infection or space occupying lesion. Unable to understand the use instruction for the ointment, as judged

2011 Clinical Trials

171. Comparative Study Between Two Fecal Management Systems

Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Bedfast patients who need to have liquid or semi-liquid stool contained away from the body to prevent skin breakdown or contamination of existing wounds Liquid to semi-liquid stool incontinence for past three days that is expected to last for extended period due to poor response to anti-diarrheal treatment Absence of contraindications listed in Exclusion Criteria If on subcutaneous anti-coagulation to prevent deep vein thrombosis, then can (...) be included in study Exclusion Criteria: Allergic to product components Rectal or anal injury or active bleeding Severe rectal or anal stricture or stenosis (distal rectum cannot accommodate the balloon), diseases of the rectal mucosa (i.e. severe proctitis, ischemic proctitis, mucosal lacerations) Rectal or anal tumors Severe hemorrhoids Fecal impaction Loss of rectal tone or prolapsed anal sphincter History of Ileo-anal anastamosis or internal rectal pouch (e.g. S or J pouch) Large Bowel (Colon) surgery

2011 Clinical Trials

172. Microbicide Safety and Acceptability in Young Men

, creatinine, coagulation, electrolyte, or hematology abnormality in accordance with DAIDS toxicity table values (normal values based on site specific laboratory criteria) at screening (or Visit 2 PT/INR for coagulation), and confirmed by retest/and or redraw History of significant gastrointestinal bleeding History of inflammatory bowel disease Abnormalities of the rectal mucosa, or significant rectal symptom(s), which in the opinion of the clinician represents a contraindication to biopsy (including (...) but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids Per participant report, anticipated use and/or unwillingness to abstain from the following medications during the period of Stage 2 study participation: Heparin, including Lovenox® Warfarin Plavix® (clopidogrel bisulfate) Aspirin >81 mg per day Non-steroidal anti-inflammatory drugs (NSAIDS) Any other drugs that are associated with increased likelihood

2011 Clinical Trials

173. Switching Study From Warfarin to Rivaroxaban

rate); Subject is tested to be HIV-1/2Ab, p24Ag, HbsAg or HCV-Ab positive; Known coagulation disorders (e.g. von Willebrand's disease, haemophiliac); Known disorders with increased bleeding risks (e.g. periodontosis, hemorrhoids, acute gastritis, peptic ulcer); Known sensitivity to common causes of bleeding (e.g. nasal); Recent or planned surgical or diagnostic procedures at the central nervous system (CNS) or eye; Subjects with hyperlipidemia (Coumadin / warfarin warning) Contacts and Locations Go (...) week to adjust their blood coagulation values to a specific level, i.e. to maintain an INR (international normalized ratio) of 2.0 - 3.0. This range is commonly used for long-term anticoagulant treatment. The first group (A) will receive rivaroxaban for four days, the second group (B) will take placebo. On the last day, all subjects in groups A and B will receive vitamin K to neutralize the effects of warfarin. The third group (C) will not undergo prior treatment with warfarin but will receive

2011 Clinical Trials

174. Editorial: Outpatient treatment of haemorrhoids. (Full text)

Editorial: Outpatient treatment of haemorrhoids. 1139171 1975 09 18 2018 11 13 0007-1447 2 5972 1975 Jun 21 British medical journal Br Med J Editorial: Outpatient treatment of haemorrhoids. 651 eng Journal Article England Br Med J 0372673 0007-1447 AIM IM J Ambulatory Care Cryosurgery Hemorrhoids surgery therapy Humans Ligation Outpatient Clinics, Hospital 750636 00015714 The estrogenic potency of combined oral contraceptives (OC) is discussed. A dose of 30-50 mcg estrogen was recommended once (...) and ethynodiol diacetate have less estrogenic action at high doses and more action at low doses. It is doubtful that the standard measure for estrogenicity in the mouse uterus is applicable to the association of thromboembolic disease and OC use. The only way to resolve the question is by a more complete epidemiological analysis, which requires greater cooperation in the reporting of thrombotic incidents. Blood Coagulation Effects Contraception Contraceptive Methods Diseases Embolism Ethynodiol Diacetate

1975 British medical journal PubMed

175. Surgery in haemophilia and allied disorders. (Full text)

Surgery in haemophilia and allied disorders. 4922847 1971 02 09 2018 11 13 0035-8843 47 3 1970 Sep Annals of the Royal College of Surgeons of England Ann R Coll Surg Engl Surgery in haemophilia and allied disorders. 125-38 Anscombe A R AR eng Historical Article Journal Article England Ann R Coll Surg Engl 7506860 0035-8843 0 Blood Coagulation Factors 9001-27-8 Factor VIII IM Q Abdomen, Acute surgery Blood Coagulation Blood Coagulation Factors Blood Platelets Factor VIII therapeutic use Female (...) Hematemesis surgery therapy Hematoma surgery Hemophilia A history surgery Hemophilia B surgery Hemorrhoids surgery therapy History, 18th Century History, 19th Century History, 20th Century Humans Male Melena surgery therapy Peptic Ulcer surgery therapy 1970 9 1 1970 9 1 0 1 1970 9 1 0 0 ppublish 4922847 PMC2387787 Br Med J. 1952 Dec 27;2(4799):1378-82 12997790 N Engl J Med. 1965 Dec 30;273(27):1443-7 5852902 Science. 1936 Sep 18;84(2177):270-1 17742899 Lancet. 1965 Nov 20;2(7421):1036-9 4159132 Proc Soc

1970 Annals of the Royal College of Surgeons of England PubMed

177. Overview of GI Bleeding

, especially of the mucous membranes, suggest (Rendu-Osler-Weber syndrome). Cutaneous nail bed and GI telangiectasia may indicate or . Testing Several tests are done to help confirm the suspected diagnosis. CBC, coagulation profile, and often other laboratory studies NGT for all but those with minimal rectal bleeding Upper endoscopy for suspected upper GI bleeding Colonoscopy for lower GI bleeding (unless clearly caused by hemorrhoids) CBC should be obtained in patients with large-volume or occult blood (...) received > 10 units of packed RBCs, the mortality rate is about 30%. Acute or chronic bleeding of internal hemorrhoids stops spontaneously in most cases. Patients with are treated via anoscopy with rubber band ligation, injection, coagulation, or surgery. Geriatrics Essentials In the elderly, and are the most common causes of minor bleeding. , , and are the most common causes of major bleeding. Variceal bleeding is less common than in younger patients. Massive GI bleeding is tolerated poorly by elderly

2013 Merck Manual (19th Edition)

178. Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

, or a disease that either causes or threatens neurologic compromise (e.g., unstable vertebral metastases). Presence of pericardial effusion Rapidly re-accumulating, symptomatic malignant pleural effusions status-post thoracentesis or pleural catheter insertion that requires immediate mechanical or chemical pleurodesis for adequate palliation. Active thrombophlebitis, thromboembolism, hypercoagulability states, bleeding, or use of anti-coagulation therapy (including lovenox, warfarin, or anti platelet agents (...) of an Esophagogastroduodenoscopy (EGD) and Colonoscopy) prior to enrollment to rule out possible reasons for bleeding. A patient will be eligible with negative results for both exams. Active GI bleeding within past 5 years other than due to benign anorectal causes such as hemorrhoids, fissures and stricture. A known allergy to any component of GC1008. Patients who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Contacts and Locations Go to Information from

2010 Clinical Trials

179. An acidic glycoconjugate from Lythrum salicaria L. with controversial effects on haemostasis. (PubMed)

and Pacula, 2002). The flowering parts and the flowering branch tips are used in traditional medicine and pharmaceuticals internally in a form of decoctions or as extracts for treatment of diarrhea, chronic intestinal catarrhs, hemorrhoids and eczema, or externally to treat varicose veins, venous insufficiency and gums (Mantle et al., 2000; Rauha et al., 2000). The aim of this study was to isolate the plant glycoconjugate from flowering parts of Lythrum salicaria, and to verify its influence on blood (...) coagulation process.From the air-dried flowering parts of this plant a water-soluble glycoconjugate has been isolated by hot alkaline extraction followed by neutralization and purification by multi-steps extraction with organic solvents, dialysis and concentration. The plant isolate was tested in vitro on anticoagulant activity on human plasma, and on Wistar rats blood system in vivo as well as ex vivo.A dark brown isolate was obtained in the yield of 8% of starting material (w/w) as a macromolecular

2010 Journal of Ethnopharmacology

180. Clinical Trial With Mesalamine 1g Suppositories

) of permitted medications within 30 days of the Baseline Visit, or any plans to change the regimen during the course of this study 11. Use or treatment with an investigational drug, therapy, or device within 30 days of the Baseline Visit 12. A planned change in tobacco usage (e.g., smoking, oral tobacco) during the study 13. Female patients who are pregnant, planning a pregnancy, or who are breastfeeding 14. Diseases interfering with the DAI assessment, including but not limited to, hemorrhoids and anal (...) examination findings indicating the same 21. Current clinically significant urinary tract obstruction 22. History of coagulation disorders, including those requiring treatment with anticoagulant drugs (except for aspirin taken at ≤325 mg/day for cardio-protective reasons 23. Current active malignancy or history of malignancy within the past five years, except for cervical carcinoma in situ, squamous or basal cell carcinoma of the skin that has been surgically removed, or prostate cancer that is being

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>